These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 17182178

  • 1. Identification of an HLA-A*0201 restricted Bcl2-derived epitope expressed on tumors.
    Wang M, Johansen B, Nissen MH, Thorn M, Kløverpris H, Fomsgaard A, Buus S, Claësson MH.
    Cancer Lett; 2007 Jun 18; 251(1):86-95. PubMed ID: 17182178
    [Abstract] [Full Text] [Related]

  • 2. Generation of cytotoxic T cell responses to an HLA-A24 restricted epitope peptide derived from wild-type p53.
    Umano Y, Tsunoda T, Tanaka H, Matsuda K, Yamaue H, Tanimura H.
    Br J Cancer; 2001 Apr 20; 84(8):1052-7. PubMed ID: 11308253
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Inhibition of tumor growth with antiangiogenic cancer vaccine using epitope peptides derived from human vascular endothelial growth factor receptor 1.
    Ishizaki H, Tsunoda T, Wada S, Yamauchi M, Shibuya M, Tahara H.
    Clin Cancer Res; 2006 Oct 01; 12(19):5841-9. PubMed ID: 17020992
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Characterization of HLA-A3-restricted cytotoxic T lymphocytes reactive against the widely expressed tumor antigen telomerase.
    Vonderheide RH, Anderson KS, Hahn WC, Butler MO, Schultze JL, Nadler LM.
    Clin Cancer Res; 2001 Nov 01; 7(11):3343-8. PubMed ID: 11705846
    [Abstract] [Full Text] [Related]

  • 9. Identification of a WT1 protein-derived peptide, WT1, as a HLA-A 0206-restricted, WT1-specific CTL epitope.
    Li Z, Oka Y, Tsuboi A, Fujiki F, Harada Y, Nakajima H, Masuda T, Fukuda Y, Kawakatsu M, Morimoto S, Katagiri T, Tatsumi N, Hosen N, Shirakata T, Nishida S, Kawakami Y, Udaka K, Kawase I, Oji Y, Sugiyama H.
    Microbiol Immunol; 2008 Nov 01; 52(11):551-8. PubMed ID: 19090835
    [Abstract] [Full Text] [Related]

  • 10. Cytotoxic T cell responses to human telomerase reverse transcriptase in patients with hepatocellular carcinoma.
    Mizukoshi E, Nakamoto Y, Marukawa Y, Arai K, Yamashita T, Tsuji H, Kuzushima K, Takiguchi M, Kaneko S.
    Hepatology; 2006 Jun 01; 43(6):1284-94. PubMed ID: 16729333
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. 5-fluorouracil-based chemotherapy enhances the antitumor activity of a thymidylate synthase-directed polyepitopic peptide vaccine.
    Correale P, Del Vecchio MT, Di Genova G, Savellini GG, La Placa M, Terrosi C, Vestri M, Urso R, Lemonnier F, Aquino A, Bonmassar E, Giorgi G, Francini G, Cusi MG.
    J Natl Cancer Inst; 2005 Oct 05; 97(19):1437-45. PubMed ID: 16204693
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. HLA-A2 and -A24-restricted glypican-3-derived peptide vaccine induces specific CTLs: preclinical study using mice.
    Motomura Y, Ikuta Y, Kuronuma T, Komori H, Ito M, Tsuchihara M, Tsunoda Y, Shirakawa H, Baba H, Nishimura Y, Kinoshita T, Nakatsura T.
    Int J Oncol; 2008 May 05; 32(5):985-90. PubMed ID: 18425324
    [Abstract] [Full Text] [Related]

  • 15. A potent immunogenic general cancer vaccine that targets survivin, an inhibitor of apoptosis proteins.
    Idenoue S, Hirohashi Y, Torigoe T, Sato Y, Tamura Y, Hariu H, Yamamoto M, Kurotaki T, Tsuruma T, Asanuma H, Kanaseki T, Ikeda H, Kashiwagi K, Okazaki M, Sasaki K, Sato T, Ohmura T, Hata F, Yamaguchi K, Hirata K, Sato N.
    Clin Cancer Res; 2005 Feb 15; 11(4):1474-82. PubMed ID: 15746049
    [Abstract] [Full Text] [Related]

  • 16. Identification and characterization of a WT1 (Wilms Tumor Gene) protein-derived HLA-DRB1*0405-restricted 16-mer helper peptide that promotes the induction and activation of WT1-specific cytotoxic T lymphocytes.
    Fujiki F, Oka Y, Tsuboi A, Kawakami M, Kawakatsu M, Nakajima H, Elisseeva OA, Harada Y, Ito K, Li Z, Tatsumi N, Sakaguchi N, Fujioka T, Masuda T, Yasukawa M, Udaka K, Kawase I, Oji Y, Sugiyama H.
    J Immunother; 2007 Apr 15; 30(3):282-93. PubMed ID: 17414319
    [Abstract] [Full Text] [Related]

  • 17. Identification of a common HLA-A*0201-restricted epitope among SSX family members by mimicking altered peptide ligands strategy.
    He Y, Mao L, Lin Z, Deng Y, Tang Y, Jiang M, Li W, Jia Z, Wang J, Ni B, Wu Y.
    Mol Immunol; 2008 May 15; 45(9):2455-64. PubMed ID: 18295890
    [Abstract] [Full Text] [Related]

  • 18. Targeting of human p53-overexpressing tumor cells by an HLA A*0201-restricted murine T-cell receptor expressed in Jurkat T cells.
    Liu X, Peralta EA, Ellenhorn JD, Diamond DJ.
    Cancer Res; 2000 Feb 01; 60(3):693-701. PubMed ID: 10676655
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Construction of expression vector of hTERT- hIL18 fusion gene and induction of cytotoxic T lymphocyte response against hTERT.
    Tong XM, Zheng SE, Bader A, Yao HP, Wu NP, Altmeyer P, Brockmeyer NH, Jin J.
    Eur J Med Res; 2008 Jan 23; 13(1):7-14. PubMed ID: 18226991
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.